Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-line treatment option for advanced NSCLC carrying EGFR mutation with or without...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Linlin, Wang, Liuchun, Wang, Jingya, Chen, Jinliang, Meng, Zhaoting, Liu, Zhujun, Jiang, Xiangli, Wang, Xinyue, Huang, Chun, Chen, Peng, Liang, Yan, Jiang, Richeng, Wang, Jing, Zhong, Diansheng, Shang, Yanhong, Zhang, Yan, Zhang, Cuiying, Huang, Dingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403846/
https://www.ncbi.nlm.nih.gov/pubmed/37543587
http://dx.doi.org/10.1186/s12943-023-01823-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403846/
https://www.ncbi.nlm.nih.gov/pubmed/37543587
http://dx.doi.org/10.1186/s12943-023-01823-w

Ejemplares similares